$ASTH
Astrana Health, Inc. Stock $asth

$asth Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024008024 Filed on February 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$404.4M	$353.0M	$1.387B
YoY Change	19.9%	20.0%	21.19%
Cost Of Revenue	$330.4M	$314.1M	$1.172B
YoY Change	14.17%	24.07%	24.03%
Gross Profit	$73.96M	$38.98M	$215.0M
YoY Change	54.57%	-5.13%	7.76%
Gross Profit Margin	18.29%	11.04%	15.5%
Selling, General & Admin	$38.72M	$37.95M	$112.6M
YoY Change	82.81%	55.24%	44.97%
% of Gross Profit	52.36%	97.35%	52.38%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$5.096M	$4.902M	$17.75M
YoY Change	18.73%	20.65%	1.17%
% of Gross Profit	6.89%	12.58%	8.26%
Operating Expenses	$43.82M	$42.85M	$130.3M
YoY Change	72.01%	50.31%	36.9%
Operating Profit	$30.14M	-$3.870M	$84.61M
YoY Change	34.71%	-130.76%	-18.85%
Interest Expense	$7.585M	$1.644M	$16.10M
YoY Change	132.03%	-2795.08%	103.31%
% of Operating Profit	25.17%		19.03%
Other Income/Expense, Net	-$6.135M	$1.856M	$5.225M
YoY Change	106.98%	14.85%	-129.61%
Pretax Income	$24.00M	$924.0K	$89.84M
YoY Change	23.67%	-91.16%	3.72%
Income Tax	$7.142M	$1.018M	$31.99M
% Of Pretax Income	29.75%	110.17%	35.61%
Net Earnings	$14.84M	$12.36M	$60.72M
YoY Change	1.46%	-575.23%	23.79%
Net Earnings / Revenue	3.67%	3.5%	4.38%
Basic Earnings Per Share	$0.31		$1.30
Diluted Earnings Per Share	$0.31	$0.26	$1.29
COMMON SHARES
Basic Shares Outstanding	55.42M shares	58.28M shares	46.55M shares
Diluted Shares Outstanding	47.70M shares		46.94M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$337.3M	$296.3M	$296.3M
YoY Change	21.01%	0.92%	0.92%
Cash & Equivalents	$334.8M	$293.8M	$293.8M
Short-Term Investments	$2.490M	$2.498M	$2.498M
Other Short-Term Assets	$17.28M	$17.45M	$17.45M
YoY Change	-22.05%	17.92%	17.92%
Inventory
Prepaid Expenses
Receivables	$182.5M	$135.8M	$135.8M
Other Receivables	$1.783M	$1.335M	$11.99M
Total Short-Term Assets	$538.8M	$461.5M	$461.5M
YoY Change	17.72%	6.06%	6.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$47.14M	$44.57M	$44.57M
YoY Change	-64.23%	-65.45%	-65.45%
Goodwill	$410.3M	$278.8M
YoY Change	48.63%	1.14%
Intangibles	$119.7M	$71.65M
YoY Change	54.11%	-6.78%
Long-Term Investments	$35.89M	$25.77M	$32.17M
YoY Change	-16.74%	-36.04%	-21.91%
Other Assets	$4.067M	$1.877M	$2.222M
YoY Change	-25.25%	-69.01%	-63.31%
Total Long-Term Assets	$687.5M	$471.9M	$471.9M
YoY Change	28.51%	-10.76%	-10.76%
TOTAL ASSETS
Total Short-Term Assets	$538.8M	$461.5M	$461.5M
Total Long-Term Assets	$687.5M	$471.9M	$471.9M
Total Assets	$1.226B	$933.4M	$933.4M
YoY Change	23.54%	-3.17%	-3.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$108.2M	$25.72M	$25.72M
YoY Change	268.75%	0.97%	0.97%
Accrued Expenses	$17.42M	$24.71M	$24.71M
YoY Change	44.86%	30.9%	30.9%
Deferred Revenue	$3.017M	$744.0K
YoY Change	77.99%	40.11%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.75M	$19.50M	$20.15M
YoY Change	3241.38%	3050.24%	1560.84%
Total Short-Term Liabilities	$355.3M	$218.7M	$218.7M
YoY Change	115.38%	48.43%	48.43%
LONG-TERM LIABILITIES
Long-Term Debt	$368.4M	$258.9M	$260.0M
YoY Change	79.78%	27.31%	27.02%
Other Long-Term Liabilities	$7.652M	$3.586M	$39.88M
YoY Change	-64.91%	-82.3%	-0.75%
Total Long-Term Liabilities	$418.6M	$303.9M	$299.8M
YoY Change	67.61%	22.61%	22.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$355.3M	$218.7M	$218.7M
Total Long-Term Liabilities	$418.6M	$303.9M	$299.8M
Total Liabilities	$773.9M	$522.6M	$319.1M
YoY Change	86.61%	32.23%	-22.37%
SHAREHOLDERS EQUITY
Retained Earnings	$258.0M	$243.1M
YoY Change	24.44%	26.19%
Common Stock	$48.00K	$47.00K
YoY Change	2.13%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$653.5M	$614.2M	$614.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.226B	$933.4M	$933.4M
YoY Change	23.54%	-3.17%	-3.17%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$14.84M	$12.36M	$60.72M
YoY Change	1.46%	-575.23%	23.79%
Depreciation, Depletion And Amortization	$5.096M	$4.902M	$17.75M
YoY Change	18.73%	20.65%	1.17%
Cash From Operating Activities	$5.977M	$19.30M	$68.23M
YoY Change	-22.58%	-77.28%	-16.93%
INVESTING ACTIVITIES
Capital Expenditures	$369.0K	$7.057M	$28.53M
YoY Change	-93.88%	696.5%	24.36%
Acquisitions	$50.65M		$6.512M
YoY Change			-60.18%
Other Investing Activities	-$70.67M	-$4.370M	-$36.99M
YoY Change	782.49%	-131.02%	-333.74%
Cash From Investing Activities	-$71.04M	-$11.43M	-$65.52M
YoY Change	406.16%	-186.56%	821.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$10.19M
YoY Change			10.18%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$106.4M	11.99M	$3.421M
YoY Change	-1598.11%	104.28%	-117.03%
NET CHANGE
Cash From Operating Activities	$5.977M	19.30M	$68.23M
Cash From Investing Activities	-$71.04M	-11.43M	-$65.52M
Cash From Financing Activities	$106.4M	11.99M	$3.421M
Net Change In Cash	$41.29M	19.87M	$6.125M
YoY Change	-407.81%	-80.9%	-88.85%
FREE CASH FLOW
Cash From Operating Activities	$5.977M	$19.30M	$68.23M
Capital Expenditures	$369.0K	$7.057M	$28.53M
Free Cash Flow	$5.608M	$12.24M	$39.70M
YoY Change	231.25%	-85.43%	-32.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5579000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5622000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	14208000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	77748000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31693000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	45741000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	46055000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17748000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17543000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1061000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	112597000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	77670000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	17748000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	17543000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	17517000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	1302048000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	104265000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	98179000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4306000	usd
CY2023	us-gaap	Interest Expense InterestExpense	16102000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001083446
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37392
CY2023	dei	Entity Registrant Name EntityRegistrantName	Astrana Health, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4472349
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1668 S. Garfield Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	2nd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Alhambra
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91801
CY2023	dei	City Area Code CityAreaCode	626
CY2023	dei	Local Phone Number LocalPhoneNumber	282-0288
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	ASTH
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1300000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55423408	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	293807000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	288027000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2498000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	5567000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10657000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1335000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1834000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17450000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14798000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	461507000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	428125000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7171000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	108536000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	71648000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	76861000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	278831000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	269053000	usd
CY2023Q4	us-gaap	Income Taxes Receivable Noncurrent IncomeTaxesReceivableNoncurrent	15943000	usd
CY2022Q4	us-gaap	Income Taxes Receivable Noncurrent IncomeTaxesReceivableNoncurrent	15943000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	26473000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	0	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	25774000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	40299000	usd
CY2023Q4	asth	Investment In Privately Held Entity That Does Not Report Net Asset Value InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue	6396000	usd
CY2022Q4	asth	Investment In Privately Held Entity That Does Not Report Net Asset Value InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue	2396000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	345000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37396000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20444000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1877000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4556000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	471854000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	538088000	usd
CY2023Q4	us-gaap	Assets Assets	933361000	usd
CY2022Q4	us-gaap	Assets Assets	966213000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	59949000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	49562000	usd
CY2023Q4	asth	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	7737000	usd
CY2022Q4	asth	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	8065000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	106657000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	81255000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4279000	usd
CY2023Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	638000	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	664000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	646000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	594000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4607000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3572000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	19500000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	619000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	18940000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	218674000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	148610000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4072000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	14217000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1033000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1275000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36289000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19915000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	258939000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	203389000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3586000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20260000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	303919000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	259056000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	522593000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	407666000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	asth	Temporary Equity Deficit Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityDeficitCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	-205883000	usd
CY2022Q4	asth	Temporary Equity Deficit Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityDeficitCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	14237000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Shares Outstanding SharesOutstanding	46843743	shares
CY2022Q4	us-gaap	Shares Outstanding SharesOutstanding	46575699	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10584340	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10299259	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	47000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	47000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	371037000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	360097000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	243134000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	182417000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	614218000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	542561000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	2433000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1749000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	616651000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	544310000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	933361000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	966213000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1386661000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1144163000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	773915000	usd
CY2023	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1171703000	usd
CY2022	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	944685000	usd
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	596142000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	62077000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	1039898000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	675736000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	84613000	usd
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	usd
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	usd
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	2193000	usd
CY2022	us-gaap	Interest Expense InterestExpense	7920000	usd
CY2021	us-gaap	Interest Expense InterestExpense	5394000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1976000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1571000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4581000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-21271000	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-10745000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6121000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3944000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3750000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5225000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17649000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20431000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	89838000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	86616000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31989000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40875000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	57849000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	45741000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	46055000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2868000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	570000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-22868000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	60717000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	45171000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	68923000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.30
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.57
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.29
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.52
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	329463000	usd
CY2021	asth	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	71690000	usd
CY2021	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	75000	usd
CY2021	asth	Stock Issued During Period Value Noncontrolling Interest StockIssuedDuringPeriodValueNoncontrollingInterest	40134000	usd
CY2021	asth	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	9061000	usd
CY2021	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	5738000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6745000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3769000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	500000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	334000	usd
CY2021	asth	Noncontrolling Interest Increase From Capital Charge NoncontrollingInterestIncreaseFromCapitalCharge	48000	usd
CY2021	asth	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	-1156000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	454107000	usd
CY2022	asth	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	48936000	usd
CY2022	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	4338000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	66000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-321000	usd
CY2022	asth	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	8633000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	9250000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	16101000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1000000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	371000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	457000	usd
CY2022	asth	Aamg Equity Contingent Consideration AAMGEquityContingentConsideration	5569000	usd
CY2022	asth	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	23893000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	544310000	usd
CY2023	asth	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	65277000	usd
CY2023	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	78000	usd
CY2023	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	106000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-933000	usd
CY2023	asth	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	1522000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	10042000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	800000	usd
CY2023	asth	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	-3904000	usd
CY2023	asth	Stockholders Equity Transfer Of Common Control Entities StockholdersEquityTransferOfCommonControlEntities	2447000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	616651000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	57849000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17517000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	939000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1078000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	22040000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16101000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6745000	usd
CY2023	asth	Noncash Lease Expense NoncashLeaseExpense	7183000	usd
CY2022	asth	Noncash Lease Expense NoncashLeaseExpense	3759000	usd
CY2021	asth	Noncash Lease Expense NoncashLeaseExpense	3133000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5579000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5622000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4306000	usd
CY2023	asth	Unrealized Gain Loss From Investment In Equity Securities UnrealizedGainLossFromInvestmentInEquitySecurities	-4782000	usd
CY2022	asth	Unrealized Gain Loss From Investment In Equity Securities UnrealizedGainLossFromInvestmentInEquitySecurities	-25506000	usd
CY2021	asth	Unrealized Gain Loss From Investment In Equity Securities UnrealizedGainLossFromInvestmentInEquitySecurities	-10845000	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	201000	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	4235000	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1071000	usd
CY2023	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1246000	usd
CY2022	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	2272000	usd
CY2021	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	2193000	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-12444000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-14278000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	7671000	usd
CY2023	asth	Gain Loss On Consolidation Of Equity Method Investment GainLossOnConsolidationOfEquityMethodInvestment	0	usd
CY2022	asth	Gain Loss On Consolidation Of Equity Method Investment GainLossOnConsolidationOfEquityMethodInvestment	-901000	usd
CY2021	asth	Gain Loss On Consolidation Of Equity Method Investment GainLossOnConsolidationOfEquityMethodInvestment	2752000	usd
CY2023	asth	Gain Loss On Equity Receivable GainLossOnEquityReceivable	0	usd
CY2022	asth	Gain Loss On Equity Receivable GainLossOnEquityReceivable	0	usd
CY2021	asth	Gain Loss On Equity Receivable GainLossOnEquityReceivable	4270000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1145000	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	usd
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	15723000	usd
CY2023	us-gaap	Proceeds From Other Operating Activities ProceedsFromOtherOperatingActivities	422000	usd
CY2022	us-gaap	Proceeds From Other Operating Activities ProceedsFromOtherOperatingActivities	0	usd
CY2021	us-gaap	Proceeds From Other Operating Activities ProceedsFromOtherOperatingActivities	189000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26735000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38194000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1518000	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-6167000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-4229000	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	20116000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-311000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-8196000	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	5351000	usd
CY2023	asth	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	2956000	usd
CY2022	asth	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	-818000	usd
CY2021	asth	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	-2708000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2864000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	243000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1529000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-170000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-49000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3217000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-328000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-2470000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	892000	usd
CY2023	asth	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	18610000	usd
CY2022	asth	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	22786000	usd
CY2021	asth	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	5279000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-14477000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	6917000	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-14005000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6674000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3945000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3215000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	68227000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	82128000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	70335000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6512000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16352000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2585000	usd
CY2023	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	2676000	usd
CY2022	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	4067000	usd
CY2021	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	56000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2151000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1854000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28000000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	491000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	31671000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	67612000	usd
CY2023	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	26473000	usd
CY2022	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	0	usd
CY2021	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	0	usd
CY2023	us-gaap	Payments To Acquire Trading Securities Heldforinvestment PaymentsToAcquireTradingSecuritiesHeldforinvestment	4000000	usd
CY2022	us-gaap	Payments To Acquire Trading Securities Heldforinvestment PaymentsToAcquireTradingSecuritiesHeldforinvestment	0	usd
CY2021	us-gaap	Payments To Acquire Trading Securities Heldforinvestment PaymentsToAcquireTradingSecuritiesHeldforinvestment	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28529000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22940000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19223000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	325000	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	13622000	usd
CY2023	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
CY2022	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
CY2021	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	6375000	usd
CY2023	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
CY2022	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	400000	usd
CY2021	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
CY2023	asth	Payments To Equity Method Investments PaymentsToEquityMethodInvestments	700000	usd
CY2022	asth	Payments To Equity Method Investments PaymentsToEquityMethodInvestments	2105000	usd
CY2021	asth	Payments To Equity Method Investments PaymentsToEquityMethodInvestments	0	usd
CY2023	asth	Proceeds From Cash Received From Consolidation Of Variable Interest Entity ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity	0	usd
CY2022	asth	Proceeds From Cash Received From Consolidation Of Variable Interest Entity ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity	0	usd
CY2021	asth	Proceeds From Cash Received From Consolidation Of Variable Interest Entity ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity	5927000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65523000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7113000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16540000	usd
CY2023	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	62074000	usd
CY2022	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	14030000	usd
CY2021	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	31089000	usd
CY2023	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	204681000	usd
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	3865000	usd
CY2021	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	238326000	usd
CY2023	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	284527000	usd
CY2022	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	3598000	usd
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	180569000	usd
CY2023	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	675000	usd
CY2022	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	561000	usd
CY2021	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	208000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1522000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8633000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9061000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10192000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	9250000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5739000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40134000	usd
CY2023	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	78000	usd
CY2022	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	5046000	usd
CY2021	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	1471000	usd
CY2023	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	0	usd
CY2022	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	436000	usd
CY2021	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	48000	usd
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3928000	usd
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	usd
CY2021	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	727000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1000000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3421000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-20085000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-47748000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6125000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54930000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	39127000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288027000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	233097000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193970000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	294152000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288027000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	233097000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	56567000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	47311000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	37201000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	14251000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6672000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	4158000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	25124000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	asth	Temporary Equity Dividends Impact TemporaryEquityDividendsImpact	3076000	usd
CY2022	asth	Temporary Equity Dividends Impact TemporaryEquityDividendsImpact	0	usd
CY2021	asth	Temporary Equity Dividends Impact TemporaryEquityDividendsImpact	0	usd
CY2023	us-gaap	Payments For Proceeds From Real Estate Partnership Investment Net PaymentsForProceedsFromRealEstatePartnershipInvestmentNet	152767000	usd
CY2022	us-gaap	Payments For Proceeds From Real Estate Partnership Investment Net PaymentsForProceedsFromRealEstatePartnershipInvestmentNet	0	usd
CY2021	us-gaap	Payments For Proceeds From Real Estate Partnership Investment Net PaymentsForProceedsFromRealEstatePartnershipInvestmentNet	0	usd
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2021Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	71000	usd
CY2023	asth	Issuance Of Financing Obligation For Business Combination IssuanceOfFinancingObligationForBusinessCombination	0	usd
CY2022	asth	Issuance Of Financing Obligation For Business Combination IssuanceOfFinancingObligationForBusinessCombination	0	usd
CY2021	asth	Issuance Of Financing Obligation For Business Combination IssuanceOfFinancingObligationForBusinessCombination	12706000	usd
CY2023	asth	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	0	usd
CY2022	asth	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	694000	usd
CY2021	asth	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	0	usd
CY2023	asth	Fixed Asset Obtained In Exchange For Finance Lease Liabilities FixedAssetObtainedInExchangeForFinanceLeaseLiabilities	486000	usd
CY2022	asth	Fixed Asset Obtained In Exchange For Finance Lease Liabilities FixedAssetObtainedInExchangeForFinanceLeaseLiabilities	971000	usd
CY2021	asth	Fixed Asset Obtained In Exchange For Finance Lease Liabilities FixedAssetObtainedInExchangeForFinanceLeaseLiabilities	0	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	800000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1000000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023	us-gaap	Mortgage Loan Related To Property Sales1 MortgageLoanRelatedToPropertySales1	0	usd
CY2022	us-gaap	Mortgage Loan Related To Property Sales1 MortgageLoanRelatedToPropertySales1	16275000	usd
CY2021	us-gaap	Mortgage Loan Related To Property Sales1 MortgageLoanRelatedToPropertySales1	0	usd
CY2023	asth	Cancellation Of Restricted Stock Awards CancellationOfRestrictedStockAwards	0	usd
CY2022	asth	Cancellation Of Restricted Stock Awards CancellationOfRestrictedStockAwards	0	usd
CY2021	asth	Cancellation Of Restricted Stock Awards CancellationOfRestrictedStockAwards	334000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	293807000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	288027000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	233097000	usd
CY2023Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	345000	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	294152000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288027000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	233097000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2024, Apollo Medical Holdings, Inc. rebranded as Astrana Health, Inc (“Astrana”). Unless the context dictates otherwise, references in these notes to the financial statements, the “Company,” “we,” “us,” “our,” and similar words are references to Astrana and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, Astrana is a leading provider-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver accessible, high-quality care to patients in a cost-effective manner. Together with Astrana’s affiliated physician groups and consolidated subsidiaries and VIEs, the Company provides value-based care enablement services and care delivery with its consolidated care partners to serve patients in California, Nevada, and Texas, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (“HMOs”), with a small portion of our revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company’s physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reportable segments changed from one to three in the first quarter of 2023 as a result of certain changes to the information regularly provided to the Company’s chief operating decision maker when reviewing the Company’s performance as well as an effort to provide additional transparency to investors and other financial statement users. The three segments identified by the Company are Care Partners, Care Delivery and Care Enablement, which are described as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Partners</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners aligned on a shared vision for coordinated care delivery. By leveraging the Company’s unique care enablement platform and ability to recruit, empower, and incentivize physicians to effectively manage total cost of care, the Company is able to organize partnered providers into successful multi-payer risk-bearing organizations that take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare fee for service (“FFS”), Medicare Advantage, Medicaid, Commercial, and Exchange. Through the Company’s network of “independent practice associations” (“IPAs”), “accountable care organizations” (“ACOs”), and Restricted Knox-Keene licensed health plan, the Company’s healthcare delivery entities are responsible for coordinating and delivering high-quality care to the Company’s patients and ensuring continuity of care in Astrana’s ecosystem across age, stage of life, or life circumstance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the Company’s Accountable Care Organizations (“ACO”) began participating in the Next Generation Accountable Care Organization (“NGACO”) Model of CMS in January 2017. The NGACO Model was a Center for Medicare & Medicaid Services (“CMS”) program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the termination of the NGACO Model on December 31, 2021, the Company’s ACO participated as a Direct Contracting Entity (“DCE”) in the standard track of CMS’s Global and Professional Direct Contracting (“GPDC”) Model for Performance Year 2022 (“PY22”), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to the current Administration’s health care priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (“ACO REACH”) Model. The Company began participation in the ACO REACH Model on January 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Delivery</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Care Delivery segment is a patient-centric, data-driven care delivery organization focused on delivering high-quality and accessible care to all patients. The Company’s care delivery organization includes primary care, multi-specialty care, and ancillary care services. This segment includes the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Primary care clinics, including post-acute care services; </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multi-specialty care clinics and medical groups, including hospitalist, intensivist, and physician advisory services, cardiac care and diagnostic testing, and specialized care for women’s health; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ancillary service providers, such as urgent care centers, outpatient imaging centers, ambulatory surgery centers, and full-service labs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Enablement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Care Enablement segment is an integrated, end-to-end clinical, operational, financial, and administrative platform, powered by the Company’s proprietary technology suite, that enhances delivery of high-quality, value-based care to patients and leading to superior clinical and financial outcomes. The Company provides solutions to providers, including independent physicians, provider and medical groups, accountable care organizations, and payers, including health plans and other risk-bearing organizations. The Company’s platform meets providers and payers where they are, with a wide spectrum of solutions across the total cost of care risk spectrum, ranging from solutions for fee-for-service entities to full risk-bearing entities, and across patient types, including Medicare, Medicaid, Commercial, and Exchange patients. This segment includes the Company’s wholly owned subsidiaries which operate as management services organizations (“MSOs”), which enter into long-term management and/or administrative services agreements with Independent Practice Associations (“IPAs”), ACOs, or clinics. By leveraging the Company’s care enablement platform, providers and payers can improve their ability to deliver high-quality care to their patients and achieve better patient outcomes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Affiliates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s other affiliates are not included as a reportable segment and primarily consist of the real estate operations and other entities that are individually immaterial. The real estate operations are deemed Excluded Assets that are solely for the benefit of Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”) and its shareholders. Excluded Assets means (i) assets received from the sale of shares of APC’s Series A Preferred equal to the Series A purchase price, (ii) the assets of APC that are not Healthcare Services Assets (as defined in the Series A Preferred purchase agreement), including APC’s equity interests in Astrana Health, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). As such, any income pertaining to Excluded Assets have no impact on the Series A Preferred dividend payable by APC to Astrana Health Medical Corporation (“Astrana Medical”), formerly known as AP-AMH Medical Corporation, and consequently will not affect net income attributable to Astrana. APC and Astrana Medical are consolidated variable interest entities of the Company. See Note 18 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s entities that qualify as consolidated VIEs. </span></div>On December 26, 2023, APC completed a restructuring transaction to spin-off its real estate investments, a component of Excluded Assets (“the Spin-Off”). To effect the restructuring, APC contributed its real estate investments to a wholly owned subsidiary in exchange for 100% of the subsidiary’s membership interest units, which membership interests were then distributed to holders of APC’s outstanding common stock as a dividend, with each such stockholder receiving one membership interest unit for each share of outstanding APC common stock held. Dr. Thomas Lam, the Company’s Vice Chairman, is the Chief Executive Officer and Chief Financial Officer and a director and stockholder of APC; Dr. Kenneth Sim, the Company’s Executive Chairman, is Chairman and a director and stockholder of APC; and Dr. Albert Young, the Company’s Chief Administrative Officer, is Senor Executive Vice President and a director and stockholder of APC. The Company leases certain properties that were spun-off and will continue to lease from these properties. After the distribution, the real estate investments became related parties since the chief executive officer of the real estate investments is also a board member of the Company. See Note 15 – “Related-Party Transactions” to the consolidated financial statements for information on related party transactions. The dividend was $190.3 million and recorded at fair value of the investments’ net assets on the date of distribution, December 26, 2023. The fair value of the dividend was measured using Level 3 inputs by applying market data of similar real estate comparables. The gain, representing the difference between the fair value and the carrying value of the net assets, was $5.3 million and is presented within other income in the accompanying consolidated statement of income. As a result of the distribution, the real estate investments are no longer included within the consolidated financial statements after December 26, 2023.
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023Q4	asth	Restructuring Spinoff Transaction Percentage RestructuringSpinoffTransactionPercentage	1
CY2023Q4	asth	Restructuring Spinoff Transaction Number Of Membership Units RestructuringSpinoffTransactionNumberOfMembershipUnits	1	unit
CY2023Q4	asth	Restructuring Spinoff Transaction Dividend Real Estate Operations RestructuringSpinoffTransactionDividendRealEstateOperations	190300000	usd
CY2023Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	5300000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between other assets and investments in privately held entities on the accompanying consolidated balance sheet as of December 31, 2022. The reclassification had no effect on net income, earnings per share, retained earnings, cash flows or total assets.</span></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combinations and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (“IBNR”) claims), determination of hospital shared-risk and health plan shared-risk revenue and receivables (including constraints, completion factors, and historical margins), income tax valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div>
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	202916000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	131268000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	71648000	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	187729000	usd
CY2022	asth	Finite And Indefinite Lived Intangible Assets Acquired FiniteAndIndefiniteLivedIntangibleAssetsAcquired	7743000	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	318900000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	324700000	usd
CY2023	asth	Risk Pool Surplus Or Deficits Settlement Period After Performance Year RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear	P18M
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div>The Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts.
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1386661000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1144163000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	773915000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	195472000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	118611000	usd
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	4	unit
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023Q4	asth	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	7700000	usd
CY2022Q4	asth	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	8100000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	700000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	500000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	76861000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12700000	usd
CY2023	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.50
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	195472000	usd
CY2023	asth	Finite And Indefinite Lived Intangible Assets Acquired FiniteAndIndefiniteLivedIntangibleAssetsAcquired	7444000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021Q4	us-gaap	Goodwill Goodwill	246416000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	21486000	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1151000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	269053000	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	7866000	usd
CY2023	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1912000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	278831000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	30047000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	132583000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	22876000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	24047000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7171000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	108536000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1700000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1800000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5100000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3700000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2100000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13700000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15400000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	12818000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	11661000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10232000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8794000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	7603000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	18390000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	69498000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	40299000	usd
CY2023	asth	Equity Method Investment Additional Investment EquityMethodInvestmentAdditionalInvestment	325000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5579000	usd
CY2023	asth	Equity Method Investments Contribution EquityMethodInvestmentsContribution	700000	usd
CY2023	asth	Equity Method Investment Adjustment To Fair Value EquityMethodInvestmentAdjustmentToFairValue	3351000	usd
CY2023	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	24480000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	25774000	usd
CY2023	asth	Equity Method Investment Adjustment To Fair Value EquityMethodInvestmentAdjustmentToFairValue	3400000	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	41715000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5622000	usd
CY2022	asth	Equity Method Investment Funding Reclassified To Loan Receivable EquityMethodInvestmentFundingReclassifiedToLoanReceivable	2125000	usd
CY2022	asth	Equity Method Investments Contribution EquityMethodInvestmentsContribution	2105000	usd
CY2022	asth	Equity Method Investments Consolidated EquityMethodInvestmentsConsolidated	6418000	usd
CY2022	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	600000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	40299000	usd
CY2023Q4	asth	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	4503000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9075000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10473000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	81255000	usd
CY2022Q4	asth	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	4229000	usd
CY2023Q4	asth	Subcontractor Ipa Risk Pool Payable SubcontractorIpaRiskPoolPayable	2529000	usd
CY2022Q4	asth	Subcontractor Ipa Risk Pool Payable SubcontractorIpaRiskPoolPayable	2415000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4407000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2709000	usd
CY2023Q4	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	9271000	usd
CY2022Q4	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	3304000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	744000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	531000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20098000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15301000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9322000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10600000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	59949000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	49562000	usd
CY2023	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852,935 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,831 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(759,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836,050)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,255 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	81255000	usd
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	55783000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	6157000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	2956000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	866501000	usd
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	646679000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-13566000	usd
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	5152000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	852935000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	651831000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	759354000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	559751000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	76696000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	67149000	usd
CY2023	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	836050000	usd
CY2022	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	626900000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	2360000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	-2415000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	106657000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	282000000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	207327000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	19500000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	619000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3561000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3319000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	258939000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	203389000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	19500000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	15750000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	21000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	22750000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	203000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	282000000	usd
CY2023Q4	asth	Unamortized Deferred Financing Costs UnamortizedDeferredFinancingCosts	6100000	usd
CY2022Q4	asth	Unamortized Deferred Financing Costs UnamortizedDeferredFinancingCosts	3300000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3600000	usd
CY2023	asth	Number Of Real Estate Loans NumberOfRealEstateLoans	3	loan
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	35434000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	35365000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	15623000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8999000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	19788000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8399000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	44433000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.355
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.471
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.411
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	55153000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	24022000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3638000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-11552000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3878000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-8806000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2726000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3793000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12444000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-14278000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7671000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31989000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40875000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31693000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.116
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.121
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.129
CY2023	asth	Effective Income Tax Rate Reconciliation Federal Rate Adjustment EffectiveIncomeTaxRateReconciliationFederalRateAdjustment	0.025
CY2022	asth	Effective Income Tax Rate Reconciliation Federal Rate Adjustment EffectiveIncomeTaxRateReconciliationFederalRateAdjustment	0.009
CY2021	asth	Effective Income Tax Rate Reconciliation Federal Rate Adjustment EffectiveIncomeTaxRateReconciliationFederalRateAdjustment	0.040
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	-0.021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	-0.011
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	-0.013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.028
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.010
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.026
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.044
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0
CY2023	asth	Effective Income Tax Rate Reconciliation Tax Credit Change In Investment Percent EffectiveIncomeTaxRateReconciliationTaxCreditChangeInInvestmentPercent	0.085
CY2022	asth	Effective Income Tax Rate Reconciliation Tax Credit Change In Investment Percent EffectiveIncomeTaxRateReconciliationTaxCreditChangeInInvestmentPercent	0.012
CY2021	asth	Effective Income Tax Rate Reconciliation Tax Credit Change In Investment Percent EffectiveIncomeTaxRateReconciliationTaxCreditChangeInInvestmentPercent	-0.021
CY2023	asth	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPercent	0.002
CY2022	asth	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPercent	0.005
CY2021	asth	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPercent	-0.001
CY2023	asth	Effective Income Tax Rate Reconciliation Undistributed Dividend Percent EffectiveIncomeTaxRateReconciliationUndistributedDividendPercent	-0.115
CY2022	asth	Effective Income Tax Rate Reconciliation Undistributed Dividend Percent EffectiveIncomeTaxRateReconciliationUndistributedDividendPercent	0.072
CY2021	asth	Effective Income Tax Rate Reconciliation Undistributed Dividend Percent EffectiveIncomeTaxRateReconciliationUndistributedDividendPercent	0.080
CY2023	asth	Effective Income Tax Rate Reconciliation Spin Off Transaction Percent EffectiveIncomeTaxRateReconciliationSpinOffTransactionPercent	0.030
CY2022	asth	Effective Income Tax Rate Reconciliation Spin Off Transaction Percent EffectiveIncomeTaxRateReconciliationSpinOffTransactionPercent	0
CY2021	asth	Effective Income Tax Rate Reconciliation Spin Off Transaction Percent EffectiveIncomeTaxRateReconciliationSpinOffTransactionPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	2831000	usd
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	2489000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1747000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	670000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	1718000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	853000	usd
CY2023Q4	asth	Deferred Tax Assets Investment DeferredTaxAssetsInvestment	1355000	usd
CY2022Q4	asth	Deferred Tax Assets Investment DeferredTaxAssetsInvestment	2145000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7551000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9383000	usd
CY2023Q4	asth	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	10897000	usd
CY2022Q4	asth	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6470000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	1284000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	8971000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	663000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1011000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28046000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31994000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5904000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8292000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	22142000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23702000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	329000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1840000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	15301000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	21268000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	9936000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	5632000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	648000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	725000	usd
CY2023Q4	asth	Deferred Tax Liabilities Deferred Expense Undistributed Dividend DeferredTaxLiabilitiesDeferredExpenseUndistributedDividend	0	usd
CY2022Q4	asth	Deferred Tax Liabilities Deferred Expense Undistributed Dividend DeferredTaxLiabilitiesDeferredExpenseUndistributedDividend	8454000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	26214000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	37919000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4072000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	14217000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8300000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-2400000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-4300000	usd
CY2023	asth	Stock Issued During Period Shares Merger StockIssuedDuringPeriodSharesMerger	41048	shares
CY2023	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	3451642	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	500000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22040000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16101000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6745000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	859850	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.88
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y2M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10300000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	140000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.87
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	215609	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	16.56
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	504241	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.03
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4700000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	466411	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	28.36
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y10M13D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4700000	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	140000	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	41603	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2800000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.32
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	32.63
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45602415	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45403085	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2022	asth	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod	900000	shares
CY2022	asth	Warrant Issued During Period Value Stock Options Exercised WarrantIssuedDuringPeriodValueStockOptionsExercised	9000000	usd
CY2022	asth	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod	900000	shares
CY2023	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1000000	usd
CY2023	asth	Claims Based On Occurrence An Aggregate Amount ClaimsBasedOnOccurrenceAnAggregateAmount	3000000	usd
CY2023	asth	Defined Contribution Plan Service Period DefinedContributionPlanServicePeriod	P6M
CY2023	asth	Defined Contribution Plan Vesting Period DefinedContributionPlanVestingPeriod	P6Y
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.30
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.57
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.29
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.52
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46553256	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44971143	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43828664	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46943140	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46553256	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44971143	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43828664	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	169125	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	30315	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46943140	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45602415	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45403085	shares
CY2023Q4	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P10Y
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2023	asth	Lessee Finance Lease Termination Period If Applicable LesseeFinanceLeaseTerminationPeriodIfApplicable	P1Y
CY2023	asth	Lessee Operating Lease Termination Period If Applicable LesseeOperatingLeaseTerminationPeriodIfApplicable	P1Y
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1700000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1800000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1600000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2023	asth	Lessee Operating Lease Option To Extend Period LesseeOperatingLeaseOptionToExtendPeriod	P5Y
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2023	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	2300000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	7771000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6622000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	675000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	564000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	103000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	70000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	1025000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	649000	usd
CY2023	us-gaap	Lease Cost LeaseCost	7524000	usd
CY2022	us-gaap	Lease Cost LeaseCost	6607000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	7783000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	6781000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	103000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	70000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	675000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	564000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	25124000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	486000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	971000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y8M23D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M28D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M28D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0602
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0550
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0524
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0492
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6927000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	719000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6749000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	556000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6342000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	302000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6038000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	243000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5844000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	6000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	21923000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	53823000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1826000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12927000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	147000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	40896000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1679000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4607000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	646000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36289000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1033000	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	asth	Number Of Operating Segments That Share Similar Characteristics NumberOfOperatingSegmentsThatShareSimilarCharacteristics	2	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1386661000	usd
CY2023	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1171703000	usd
CY2023	asth	General And Administrative Expenses And Depreciation And Amortization GeneralAndAdministrativeExpensesAndDepreciationAndAmortization	130345000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	1302048000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	84613000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1144163000	usd
CY2022	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	944685000	usd
CY2022	asth	General And Administrative Expenses And Depreciation And Amortization GeneralAndAdministrativeExpensesAndDepreciationAndAmortization	95213000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	1039898000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	104265000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	773915000	usd
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	596142000	usd
CY2021	asth	General And Administrative Expenses And Depreciation And Amortization GeneralAndAdministrativeExpensesAndDepreciationAndAmortization	79594000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	675736000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	98179000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	4842000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2150000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	348000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	7340000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	22088000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	135235000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5567000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	145866000	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	21259000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21259000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1577000	usd
CY2023	asth	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Paid FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationPaid	1000000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21836000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	300000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5600000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	6629000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	19169000	usd
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-4052000	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2272000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	2577000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	21441000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	2400000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-008024-index-headers.html	Edgar Link	pending
0001628280-24-008024-index.html	Edgar Link	pending
0001628280-24-008024.txt	Edgar Link	pending
0001628280-24-008024-xbrl.zip	Edgar Link	pending
asth-20231231.htm	Edgar Link	pending
asth-20231231.xsd	Edgar Link	pending
asth-20231231xexx211.htm	Edgar Link	pending
asth-20231231xexx231.htm	Edgar Link	pending
asth-20231231xexx311.htm	Edgar Link	pending
asth-20231231xexx312.htm	Edgar Link	pending
asth-20231231xexx32.htm	Edgar Link	pending
asth-20231231_g1.jpg	Edgar Link	pending
asth-20231231_g2.jpg	Edgar Link	pending
exhibit101-2015equityincen.htm	Edgar Link	pending
exhibit1011-physiciansha.htm	Edgar Link	pending
exhibit1011-physiciansha001.jpg	Edgar Link	pending
exhibit1011-physiciansha002.jpg	Edgar Link	pending
exhibit1011-physiciansha003.jpg	Edgar Link	pending
exhibit1011-physiciansha004.jpg	Edgar Link	pending
exhibit1011-physiciansha005.jpg	Edgar Link	pending
R32.htm	Edgar Link	pending
asth-20231231_def.xml	Edgar Link	unprocessable
asth-20231231_pre.xml	Edgar Link	unprocessable
asth-20231231_lab.xml	Edgar Link	unprocessable
asth-20231231_htm.xml	Edgar Link	completed
exhibit1011-physiciansha006.jpg	Edgar Link	pending
exhibit1011-physiciansha007.jpg	Edgar Link	pending
exhibit1011-physiciansha008.jpg	Edgar Link	pending
exhibit1011-physiciansha009.jpg	Edgar Link	pending
exhibit1011-physiciansha010.jpg	Edgar Link	pending
exhibit1011-physiciansha011.jpg	Edgar Link	pending
exhibit1011-physiciansha012.jpg	Edgar Link	pending
exhibit1011-physiciansha013.jpg	Edgar Link	pending
exhibit102-formofrestricte.htm	Edgar Link	pending
exhibit103-formofrestricte.htm	Edgar Link	pending
exhibit104-formofincentive.htm	Edgar Link	pending
exhibit1048-astranaemploye.htm	Edgar Link	pending
exhibit1049-astrananonqual.htm	Edgar Link	pending
exhibit105-formofnonqualif.htm	Edgar Link	pending
exhibit1054-astranaxemploy.htm	Edgar Link	pending
exhibit1057-formofstockopt.htm	Edgar Link	pending
exhibit1058-formofrestrict.htm	Edgar Link	pending
exhibit1059-formofrestrict.htm	Edgar Link	pending
exhibit1060-kumaremploym.htm	Edgar Link	pending
exhibit1060-kumaremploym001.jpg	Edgar Link	pending
exhibit1060-kumaremploym002.jpg	Edgar Link	pending
exhibit1060-kumaremploym003.jpg	Edgar Link	pending
exhibit1060-kumaremploym004.jpg	Edgar Link	pending
exhibit1060-kumaremploym005.jpg	Edgar Link	pending
exhibit1060-kumaremploym006.jpg	Edgar Link	pending
exhibit1060-kumaremploym007.jpg	Edgar Link	pending
exhibit1060-kumaremploym008.jpg	Edgar Link	pending
exhibit1060-kumaremploym009.jpg	Edgar Link	pending
exhibit1060-kumaremploym010.jpg	Edgar Link	pending
exhibit1060-kumaremploym011.jpg	Edgar Link	pending
exhibit1060-kumaremploym012.jpg	Edgar Link	pending
exhibit1060-kumaremploym013.jpg	Edgar Link	pending
exhibit1060-kumaremploym014.jpg	Edgar Link	pending
exhibit1060-kumaremploym015.jpg	Edgar Link	pending
exhibit1061-loanandsecur.htm	Edgar Link	pending
exhibit1061-loanandsecur001.jpg	Edgar Link	pending
exhibit1061-loanandsecur002.jpg	Edgar Link	pending
exhibit1061-loanandsecur003.jpg	Edgar Link	pending
exhibit1061-loanandsecur004.jpg	Edgar Link	pending
exhibit1061-loanandsecur005.jpg	Edgar Link	pending
exhibit1061-loanandsecur006.jpg	Edgar Link	pending
exhibit1061-loanandsecur007.jpg	Edgar Link	pending
exhibit1061-loanandsecur008.jpg	Edgar Link	pending
exhibit1061-loanandsecur009.jpg	Edgar Link	pending
exhibit1061-loanandsecur010.jpg	Edgar Link	pending
exhibit1061-loanandsecur011.jpg	Edgar Link	pending
exhibit1061-loanandsecur012.jpg	Edgar Link	pending
exhibit1061-loanandsecur013.jpg	Edgar Link	pending
exhibit1061-loanandsecur014.jpg	Edgar Link	pending
exhibit1061-loanandsecur015.jpg	Edgar Link	pending
exhibit1061-loanandsecur016.jpg	Edgar Link	pending
exhibit1061-loanandsecur017.jpg	Edgar Link	pending
exhibit1061-loanandsecur018.jpg	Edgar Link	pending
exhibit1061-loanandsecur019.jpg	Edgar Link	pending
exhibit1061-loanandsecur020.jpg	Edgar Link	pending
exhibit1061-loanandsecur021.jpg	Edgar Link	pending
exhibit1061-loanandsecur022.jpg	Edgar Link	pending
exhibit1061-loanandsecur023.jpg	Edgar Link	pending
exhibit1061-loanandsecur024.jpg	Edgar Link	pending
exhibit1061-loanandsecur025.jpg	Edgar Link	pending
exhibit1061-loanandsecur026.jpg	Edgar Link	pending
exhibit1061-loanandsecur027.jpg	Edgar Link	pending
exhibit1062-securedpromi.htm	Edgar Link	pending
exhibit1062-securedpromi001.jpg	Edgar Link	pending
exhibit1062-securedpromi002.jpg	Edgar Link	pending
exhibit1062-securedpromi003.jpg	Edgar Link	pending
exhibit1062-securedpromi004.jpg	Edgar Link	pending
exhibit191-insidertradingp.htm	Edgar Link	pending
exhibit41-descriptionofsec.htm	Edgar Link	pending
exhibit971-asthxcompensati.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
asth-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASTH
Astrana Health, Inc. Stock $asth

2024 Q1 Form 10-K Financial Statement

#000162828024008024 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH Astrana Health, Inc. Stock $asth

2024 Q1 Form 10-K Financial Statement

#000162828024008024 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH
Astrana Health, Inc. Stock $asth